ArticlePloS one2017

GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.

Michaël Esquerré et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.